NASDAQ : ALGS
Aligos Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 4.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Aligos Therapeutics, Inc. (ALGS) reported revenue of 31.52M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 31.52M | 2.19M | 3.94M | 15.53M | 13.91M | 4.36M |
| Cost of Revenue | 88.38M | 69.45M | 70.27M | 73.04M | 85.08M | 104.15M |
| Gross Profit | -56.86M | -67.27M | -66.32M | -57.51M | -71.17M | -99.79M |
| Selling, General & Admin | 22.14M | 20.72M | 22.83M | 29.89M | 26.41M | 28.53M |
| Operating Expenses | 22.14M | 20.72M | 22.83M | 29.89M | 26.41M | 28.53M |
| Operating Income | -78.99M | -87.98M | -89.15M | -87.40M | -97.58M | -128.32M |
| Interest & Investment Income | 1.31M | 2.16M | 1.67M | 4.30M | 1.52M | 242.00K |
| Currency Exchange Gain (Loss) | 200.00K | 200.00K | -45.70K | -42.00K | -6.00K | |
| Other Non Operating Income (Expenses) | 4.74M | 61.74M | -43.40M | -3.01M | 161.00K | -104.00K |
| EBT Excluding Unusual Items | -72.75M | -23.88M | -130.88M | -86.16M | -95.94M | -128.19M |
| Asset Writedown | -724.00K | |||||
| Pretax Income | -72.75M | -23.88M | -130.88M | -86.88M | -95.94M | -128.19M |
| Income Tax Expense | 3.21M | 314.00K | 331.00K | 795.00K | 106.00K | 143.00K |
| Net Income | -75.96M | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
| Net Income to Common | -75.96M | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
| Shares Outstanding (Basic) | 10.40M | 9.88M | 6.26M | 2.56M | 1.71M | 1.59M |
| Shares Outstanding (Diluted) | 10.40M | 9.88M | 6.26M | 2.56M | 1.71M | 1.59M |
| EPS (Basic) | -7.30 | -2.45 | -20.94 | -34.20 | -56.24 | -80.50 |
| EPS (Diluted) | -7.31 | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 |
| Free Cash Flow | -94.52M | -82.94M | -80.87M | -79.02M | -80.33M | -116.55M |
| Free Cash Flow Per Share | -9.09 | -8.39 | -12.91 | -30.82 | -47.04 | -73.11 |
| Operating Margin | -250.63% | -4,024.93% | -2,259.92% | -562.84% | -701.66% | -2,943.82% |
| Profit Margin | -241.01% | -1,106.72% | -3,326.01% | -564.62% | -690.63% | -2,944.07% |
| Free Cash Flow Margin | -299.90% | -3,794.15% | -2,050.01% | -508.83% | -577.64% | -2,673.87% |
| EBITDA | -77.92M | -87.06M | -88.13M | -85.84M | -95.27M | -125.30M |
| D&A For EBITDA | 1.08M | 930.00K | 1.03M | 1.56M | 2.31M | 3.02M |
| EBIT | -78.99M | -87.98M | -89.15M | -87.40M | -97.58M | -128.32M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 30.38M | 18.30M | 37.00M | 135.70M | 81.35M | 186.82M |
| Short-Term Investments | 59.54M | 19.94M | 44.48M | 3.92M | ||
| Cash & Short-Term Investments | 30.38M | 77.84M | 56.94M | 135.70M | 125.83M | 190.73M |
| Restricted Cash | 42.00K | 110.00K | 110.00K | 70.00K | 115.00K | 164.00K |
| Other Current Assets | 3.93M | 4.91M | 5.09M | 5.31M | 7.60M | 13.53M |
| Total Current Assets | 62.13M | 82.86M | 62.14M | 141.08M | 133.54M | 204.42M |
| Property, Plant & Equipment | 3.44M | 4.96M | 7.33M | 9.82M | 12.51M | 14.97M |
| Long-Term Investments | 15.11M | |||||
| Other Long-Term Assets | 759.00K | 715.00K | 627.00K | 625.00K | 634.00K | 866.00K |
| Total Assets | 66.33M | 88.53M | 70.09M | 151.53M | 146.69M | 235.37M |
| Accounts Payable | 6.43M | 3.98M | 2.57M | 2.52M | 4.74M | 3.02M |
| Accrued Expenses | 18.70M | 13.53M | 15.56M | 16.84M | 16.04M | 25.39M |
| Current Portion of Leases | 3.22M | 3.73M | 3.46M | 3.24M | 3.14M | 2.91M |
| Current Unearned Revenue | 151.00K | 1.31M | 9.21M | 7.64M | ||
| Total Current Liabilities | 28.34M | 21.23M | 21.74M | 23.91M | 33.13M | 38.96M |
| Long-Term Leases | 288.00K | 1.52M | 4.92M | 7.90M | 9.43M | 11.55M |
| Long-Term Unearned Revenue | 233.00K | |||||
| Other Long-Term Liabilities | 5.81M | 12.23M | 72.41M | 27.64M | 133.00K | |
| Total Liabilities | 34.44M | 34.99M | 99.07M | 59.45M | 42.79M | 50.64M |
| Common Stock | 9.00K | 9.00K | 8.00K | 7.00K | 4.00K | 4.00K |
| Additional Paid-In Capital | 698.18M | 695.27M | 588.58M | 578.33M | 502.61M | 487.35M |
| Retained Earnings | -666.75M | -642.20M | -618.01M | -486.80M | -399.12M | -303.07M |
| Comprehensive Income & Other | 437.00K | 468.00K | 451.00K | 545.00K | 401.00K | 452.00K |
| Total Common Equity | 31.88M | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
| Shareholders' Equity | 31.88M | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
| Total Liabilities & Equity | 66.33M | 88.53M | 70.09M | 151.53M | 146.69M | 235.37M |
| Total Debt | 3.50M | 5.25M | 8.38M | 11.14M | 12.57M | 14.46M |
| Net Cash (Debt) | 26.88M | 72.59M | 48.56M | 124.57M | 113.25M | 176.28M |
| Net Cash Per Share | 2.58 | 7.34 | 7.75 | 48.59 | 66.31 | 110.57 |
| Filing Date Shares Outstanding | 6.24M | 6.19M | 6.11M | 3.03M | 1.72M | 1.71M |
| Total Common Shares Outstanding | 6.24M | 6.18M | 3.86M | 3.00M | 1.72M | 1.71M |
| Working Capital | 33.78M | 61.63M | 40.40M | 117.18M | 100.42M | 165.47M |
| Book Value Per Share | 5.11 | 8.67 | -7.50 | 30.65 | 60.52 | 108.18 |
| Tangible Book Value | 31.88M | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
| Tangible Book Value Per Share | 5.11 | 8.67 | -7.50 | 30.65 | 60.52 | 108.18 |
| Machinery | 8.38M | 8.31M | 8.04M | 7.91M | 8.28M | 7.48M |
| Construction In Progress | 4.00K | 4.00K | 22.00K | 22.00K | ||
| Leasehold Improvements | 6.26M | 6.26M | 6.10M | 6.10M | 6.09M | 5.94M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -75.96M | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
| Depreciation & Amortization | 1.08M | 930.00K | 1.03M | 3.07M | 3.67M | 3.78M |
| Loss (Gain) From Sale of Assets | 17.00K | |||||
| Asset Writedown & Restructuring Costs | 724.00K | |||||
| Loss (Gain) From Sale of Investments | -1.65M | -2.19M | -1.78M | -424.00K | -159.00K | 86.00K |
| Stock-Based Compensation | 5.60M | 5.04M | 8.45M | 12.65M | 14.69M | 13.46M |
| Other Operating Activities | -1.43M | -58.31M | 47.73M | 2.17M | ||
| Change in Accounts Payable | 2.53M | 1.41M | 54.00K | -2.22M | 1.72M | -313.00K |
| Change in Unearned Revenue | -579.00K | -151.00K | -1.16M | -8.13M | 2.50M | -4.36M |
| Change in Other Net Operating Assets | 4.01M | -5.05M | -3.85M | 829.00K | -5.78M | 21.00K |
| Operating Cash Flow | -94.17M | -82.50M | -80.74M | -79.00M | -79.39M | -115.66M |
| Capital Expenditures | -355.00K | -437.00K | -130.00K | -19.00K | -943.00K | -892.00K |
| Investment in Securities | 105.95M | -37.39M | -18.15M | 45.00M | -25.35M | 3.91M |
| Investing Cash Flow | 105.59M | -37.83M | -18.28M | 44.98M | -26.29M | 3.02M |
| Long-Term Debt Repaid | -14.00K | -83.00K | -96.00K | -61.00K | -79.00K | |
| Total Debt Repaid | -91.00K | -14.00K | -83.00K | -96.00K | -61.00K | -79.00K |
| Net Debt Issued (Repaid) | -91.00K | -14.00K | -83.00K | -96.00K | -61.00K | -79.00K |
| Issuance of Common Stock | 319.00K | 101.65M | 438.00K | 18.02M | 225.00K | 79.63M |
| Other Financing Activities | 70.41M | -875.00K | ||||
| Financing Cash Flow | 228.00K | 101.64M | 355.00K | 88.33M | 164.00K | 78.68M |
| Net Cash Flow | 11.65M | -18.69M | -98.67M | 54.31M | -105.52M | -33.96M |
| Free Cash Flow | -94.52M | -82.94M | -80.87M | -79.02M | -80.33M | -116.55M |
| Free Cash Flow Margin | -299.90% | -3,794.15% | -2,050.01% | -508.83% | -577.64% | -2,673.87% |
| Free Cash Flow Per Share | -9.09 | -8.39 | -12.91 | -30.82 | -47.04 | -73.11 |
| Levered Free Cash Flow | -61.39M | -50.04M | -48.58M | -45.91M | -43.65M | -62.76M |
| Unlevered Free Cash Flow | -61.39M | -50.04M | -48.58M | -45.91M | -43.65M | -62.76M |
| Change in Working Capital | -21.82M | -3.79M | -4.96M | -9.53M | -1.55M | -4.65M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 29.97M | 57.35M | 147.87M | 49.75M | 40.80M | 505.85M |
| Enterprise Value | 3.10M | -35.68M | 82.08M | -8.90M | -88.47M | 276.09M |
| Last Close Price | 4.80 | 9.32 | 39.84 | 16.60 | 23.82 | 296.75 |
| PS Ratio | 0.95 | 26.24 | 37.48 | 3.20 | 2.93 | 116.05 |
| PB Ratio | 0.94 | 1.07 | -5.10 | 0.54 | 0.39 | 2.74 |
| P/TBV Ratio | 0.94 | 1.07 | 0.54 | 0.39 | 2.74 | |
| EV/Sales Ratio | 0.10 | 20.81 | 63.34 | |||
| Debt / Equity Ratio | 0.11 | 0.10 | -0.29 | 0.12 | 0.12 | 0.08 |
| Net Debt / Equity Ratio | -0.84 | -1.36 | 1.68 | -1.35 | -1.09 | -0.95 |
| Net Debt / EBITDA Ratio | 0.34 | 0.83 | 0.55 | 1.45 | 1.19 | 1.41 |
| Net Debt / FCF Ratio | 0.28 | 0.88 | 0.60 | 1.58 | 1.41 | 1.51 |
| Asset Turnover | 0.31 | 0.03 | 0.04 | 0.10 | 0.07 | 0.02 |
| Quick Ratio | 2.05 | 3.67 | 2.62 | 5.68 | 3.80 | 4.90 |
| Current Ratio | 2.19 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 |
| Return on Equity (ROE) | -113.59% | -196.91% | -415.84% | -89.48% | -66.55% | -63.41% |
| Return on Assets (ROA) | -49.12% | -69.33% | -50.29% | -36.63% | -31.92% | -32.04% |
| Return on Capital Employed (ROCE) | -208.00% | -130.70% | -184.40% | -68.50% | -85.90% | -65.30% |
| Earnings Yield | -152.37% | -42.18% | -88.73% | -176.22% | -235.41% | -25.37% |
| FCF Yield | -315.35% | -144.62% | -54.69% | -158.81% | -196.90% | -23.04% |
| Buyback Yield / Dilution | -32.81% | -57.79% | -144.38% | -50.10% | -7.12% | -299.03% |